Risk factors

Kura Oncology (KURA) risk factors

Item 1A of every Kura Oncology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open KURA in Gloom →
Kura Oncology's chart, financials and news, free in your browser.Open KURA in Gloom →
  • FY2025 10-K risk factors
    85 risks20 new17 dropped28 reworded

    Transitioning from clinical stage to commercial stage following the approval of KOMZIFTI for NPM1-mutated AML in November 2025. Facing new execution, regulatory compliance, co-promotion, and commercialization risks.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors
    82 risks

    Kura Oncology faces heavy clinical, regulatory, and financial risks as a pre-revenue biopharmaceutical company with no approved products.

    Filed Feb 28, 2025